Search
Influenza A virus A/Victoria/2454/2019 IVR-207 (H1N1) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB15711ApprovedWithdrawnThis defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it
Influenza B virus B/Victoria/705/2018 BVR-11 antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB15713ApprovedWithdrawnThis defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it
Influenza A virus A/Hong Kong/2671/2019 NIB-121 (H3N2) antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB15715ApprovedWithdrawnThis defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it
Influenza B virus B/Washington/02/2019 antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB15716ApprovedWithdrawnThis defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it
Influenza A virus A/Hawaii/66/2019 (H1N1) live (attenuated) antigen
go.drugbank.com/drugs/DB15756ApprovedThis defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it
Influenza B virus B/Washington/02/2019 live (attenuated) antigen
go.drugbank.com/drugs/DB15758ApprovedThis defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it
Influenza A virus A/Tasmania/503/2020 IVR-221 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB16705ApprovedThis defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it
Influenza A virus A/Cambodia/e0826360/2020 IVR-224 (H3N2) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB16723ApprovedWithdrawnThis defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it
Influenza A virus A/Cambodia/e0826360/2020 IVR-224 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB16725ApprovedWithdrawnThis defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it
ILY101
go.drugbank.com/drugs/DB05059InvestigationalILY101 is a metal-free, non-absorbed polymeric drug designed for the selective binding and removal of phosphate anions from the gastrointestinal tract. ILY101 is being developed for the treatment of hyperphosphatemia in CKD patients on d...